Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - hydroxychloroquine sulfate - oral tablet - 200mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - hydroxychloroquine sulfate - oral tablet - 200mg

Amerika Serikat - Inggris - NLM (National Library of Medicine)

avpak - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - malaria hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to p. falciparum, p. malariae, p. ovale , and p. vivax. hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use in malaria - hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. - hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquine- resistant strains of plasmodium species (see clinical pharmacology – microbiology ). - hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. - hydroxychloroquine sulfate tablets does not prevent relapses of p. vivax or p. ovale because it is not active against the hypnozoite forms of these parasites. for radical cure of p. vivax and p. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see clinical pharmacology – microbiology ). prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the centers for disease control and prevention (cdc) malaria website   ( http://www.cdc.gov/malaria ).   lupus erythematosus hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. rheumatoid arthritis hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. use of hydroxychloroquine sulfate tablets is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydroxychloroquine sulfate, quantity: 200 mg - tablet - excipient ingredients: hypromellose; colloidal anhydrous silica; calcium hydrogen phosphate; polysorbate 80; pregelatinised maize starch; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - rheumatoid arthritis; mild systemic and discoid lupus erythematosus; the suppression and treatment of malaria.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

zydus lifesciences limited - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - malaria   hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to p. falciparum , p. malariae , p. ovale , and p. vivax . hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use in malaria - hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. - hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquine-resistant strains of plasmodium species (see clinical pharmacology – microbiology ). hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. - hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. - hy

Malta - Inggris - Medicines Authority

elc group s.r.o. pobrezni 394/12, karlin 186 00 prague 8, czech republic - phloroglucinol dihydrate - orodispersible tablet - phloroglucinol dihydrate 80 mg - drugs for functional gastrointestinal disorders

Malta - Inggris - Medicines Authority

ipca produtos farmaceuticos unipessoal lda rua jose nogueira vaz no 8b 2625-099 povoa de santa iria , portugal - film-coated tablet - hydroxychloroquine sulfate 200 mg - antiprotozoals

Amerika Serikat - Inggris - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate tablets, usp are indicated for the treatment of uncomplicated malaria due to p. falciparum , p. malariae , p. ovale , and p. vivax .   hydroxychloroquine sulfate tablets, usp are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use in malaria   - hydroxychloroquine sulfate tablets, usp are not recommended for the treatment of complicated malaria. - hydroxychloroquine sulfate tablets, usp are not effective against chloroquine or hydroxychloroquine-resistant strains of plasmodium species (seeclinical pharmacology – microbiology) . hydroxychloroquine sulfate tablets, usp are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. - hydroxychloroquine sulfate tablets, usp are not recommended for malaria prophylaxis in geographic areas where chloroquine

Amerika Serikat - Inggris - NLM (National Library of Medicine)

ncs healthcare of ky, llc dba vangard labs - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate is indicated for the treatment of uncomplicated malaria due to p. falciparum , p. malariae , p. ovale , and p. vivax . hydroxychloroquine sulfate is indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use in malaria - hydroxychloroquine sulfate is not recommended for the treatment of complicated malaria. hydroxychloroquine sulfate is not recommended for the treatment of complicated malaria. - hydroxychloroquine sulfate is not effective against chloroquine or hydroxychloroquine-resistant strains of plasmodium species (see clinical pharmacology - microbiology ). hydroxychloroquine sulfate is not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. hydroxychloroquine sulfate is not effective against chloroquine or hydroxychloroquine-resistant strains of plasmodium species (see clinical pharmacology - mi

Amerika Serikat - Inggris - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate tablets are indicated for the: - treatment of uncomplicated malaria due to susceptible strains of p. falciparum, p.malariae, p. ovale , and p.vivax. - prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. - treatment of extraintestinal amebiasis. chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. limitations of use in malaria: - do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). - do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, resistance to chloroquine phosphate tablets are widespread in p. falciparum, and is reported in p.vivax (see warnings ). - concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver s